Recognized leaders in medical science for more than a century.
Daiichi Sankyo's heritage of scientific discovery spans 110 years — from the discovery of epinephrine (also known as adrenaline) and the development of the statin class of lipid-lowering agents to the development of the first glitazone, which revolutionized long-term control of type 2 diabetes.
Today, our products are helping patients in more than 54 countries around the world including Japan, Asia, Europe and the United States. Click here to download an easy to read company history overview.
Daiichi Sankyo around the globe
Daiichi Sankyo Co., Ltd. was established in 2005 with the merger of two leading century-old pharmaceutical companies, Daiichi Pharmaceutical Co.,Ltd. and Sankyo Co., Ltd. Daiichi Sankyo maintains a portfolio of marketed pharmaceuticals for hypertension, hyperlipidemia, and bacterial infections around the world and also focuses on the discovery of novel oncology therapies. Headquartered in Tokyo, the company is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets.
Daiichi Sankyo, Inc. began operating in the U.S. in 2006. It is the U.S. subsidiary of DAIICHI SANKYO, COMPANY, LTD. and a member of the Daiichi Sankyo Group. The organization, which includes U.S. commercial operations and global clinical development (Daiichi Sankyo Pharma Development), is headquartered in New Jersey.
DAIICHI SANKYO EUROPE, GhbH (DSE), the European subsidiary, is headquartered in Munich, Germany. The organization is responsible for development and manufacturing for 12 European countries.
